101 related articles for article (PubMed ID: 23006941)
1. What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?
Kenkre VP; Kahl BS
Cancer J; 2012; 18(5):383-9. PubMed ID: 23006941
[TBL] [Abstract][Full Text] [Related]
2. Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
Griffiths R; Gleeson M; Reyes C; Knopf K; Danese M
Am J Hematol; 2010 Dec; 85(12):963-7. PubMed ID: 20981680
[No Abstract] [Full Text] [Related]
3. Follicular lymphoma: emerging therapeutic strategies.
Kenkre VP; Kahl BS
Expert Rev Hematol; 2010 Aug; 3(4):485-95. PubMed ID: 21083037
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.
Kumar R; Galardy PJ; Dogan A; Rodriguez V; Khan SP
Pediatr Blood Cancer; 2011 Aug; 57(2):317-20. PubMed ID: 21462303
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
7. [Antibody therapy in hematology and oncology - part 1].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
[No Abstract] [Full Text] [Related]
8. Comparative effectiveness of treatments for newly diagnosed follicular non-Hodgkin lymphoma.
Messori A; Fadda V; Maratea D; Trippoli S
Leuk Lymphoma; 2015; 56(9):2728-30. PubMed ID: 25651429
[No Abstract] [Full Text] [Related]
9. New treatment options have changed the survival of patients with follicular lymphoma.
Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
[TBL] [Abstract][Full Text] [Related]
10. Counterpoint: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
Barr PM
Oncology (Williston Park); 2018 Aug; 32(8):404, 407-9. PubMed ID: 30153320
[No Abstract] [Full Text] [Related]
11. Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here?
Gordon LI
Lancet Haematol; 2018 Sep; 5(9):e381-e382. PubMed ID: 30172340
[No Abstract] [Full Text] [Related]
12. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
[No Abstract] [Full Text] [Related]
14. Current immunochemotherapy strategies in follicular lymphoma.
Giné E; Gutiérrez-García G; López-Guillermo A
Adv Ther; 2010 Oct; 27(10):704-13. PubMed ID: 20820973
[TBL] [Abstract][Full Text] [Related]
15. [How to improve the efficacy of R-CHOP for indolent B-cell lymphoma?].
Tobinai K
Rinsho Ketsueki; 2012 Jun; 53(6):609-17. PubMed ID: 22790636
[No Abstract] [Full Text] [Related]
16. Does monocyte count have prognostic significance in cancer?
Tadmor T
Leuk Res; 2013 Oct; 37(10):1193-4. PubMed ID: 23953915
[No Abstract] [Full Text] [Related]
17. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
18. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
